The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer.

Antony, Jane

The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer. [electronic resource] - EMBO reports 08 2018

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1469-3178

10.15252/embr.201745670 doi


Animals
Benzocycloheptenes--pharmacology
Cell Adhesion Molecules--metabolism
Cell Line, Tumor
Cell Movement--drug effects
Cell Survival--drug effects
Chickens
Cholesterol--metabolism
Enzyme Activation--drug effects
Epithelial Cells--drug effects
Fallopian Tubes--pathology
Female
GPI-Linked Proteins--metabolism
Gene Silencing--drug effects
Humans
Intercellular Signaling Peptides and Proteins--metabolism
MAP Kinase Signaling System--drug effects
Membrane Microdomains--metabolism
Neoplasm Invasiveness
Ovarian Neoplasms--metabolism
Phosphorylation--drug effects
Protein Binding--drug effects
Proto-Oncogene Proteins--metabolism
Receptor Protein-Tyrosine Kinases--metabolism
Receptor-Like Protein Tyrosine Phosphatases, Class 5--metabolism
Treatment Outcome
Triazoles--pharmacology
Tumor Suppressor Proteins--metabolism
Axl Receptor Tyrosine Kinase